Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2022 Jan;175(1):119-126.
doi: 10.7326/M21-3669. Epub 2021 Nov 2.

Update on and Future Directions for Use of Anti-SARS-CoV-2 Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19

César Boggiano  1 , Robert W Eisinger  2 , Andrea M Lerner  3 , James M Anderson  2 , Janet Woodcock  4 , Anthony S Fauci  3 , Francis S Collins  2
Affiliations

Update on and Future Directions for Use of Anti-SARS-CoV-2 Antibodies: National Institutes of Health Summit on Treatment and Prevention of COVID-19

César Boggiano et al. Ann Intern Med. 2022 Jan.

Abstract

As the fourth wave of the SARS-CoV-2 pandemic encircles the globe, there remains an urgent challenge to identify safe and effective treatment and prevention strategies that can be implemented in a range of health care and clinical settings. Substantial advances have been made in the use of anti-SARS-CoV-2 antibodies to mitigate the morbidity and mortality associated with COVID-19. On 15 June 2021, the National Institutes of Health, in collaboration with the U.S. Food and Drug Administration, convened a virtual summit to summarize existing knowledge on anti-SARS-CoV-2 antibodies and to identify key unanswered scientific questions to further catalyze the clinical development and implementation of antibodies.

PubMed Disclaimer

Conflict of interest statement

Disclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=M21-3669.

References

    1. World Health Organization. WHO Coronavirus (COVID-19) Dashboard. 2021. Accessed at https://covid19.who.int on 30 September 2021.
    1. Gharbharan A , Jordans CCE , GeurtsvanKessel C , et al. Effects of potent neutralizing antibodies from convalescent plasma in patients hospitalized for severe SARS-CoV-2 infection. Nat Commun. 2021;12:3189. [PMID: ] doi:10.1038/s41467-021-23469-2 - DOI - PMC - PubMed
    1. Marcotte H, Hammarström L. Passive immunization: toward magic bullets. In: Mestecky J, Strober W, Russell MW, et al, eds. Mucosal Immunology. 4th ed. Elsevier; 2015:1403-34. doi:10.1016/B978-0-12-415847-4.00071-9
    1. Wooding DJ , Bach H . Treatment of COVID-19 with convalescent plasma: lessons from past coronavirus outbreaks. Clin Microbiol Infect. 2020;26:1436-1446. [PMID: ] doi:10.1016/j.cmi.2020.08.005 - DOI - PMC - PubMed
    1. U.S. Food and Drug Administration. Coronavirus disease 2019 (COVID-19) EUA information. 2021. Accessed at www.fda.gov/emergency-preparedness-and-response/mcm-legal-regulatory-and... on 30 September 2021.

Publication types

MeSH terms

Substances